2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

cell aggregation

" in MedChemExpress (MCE) Product Catalog:

73

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

6

Biochemical Assay Reagents

6

Peptides

12

Natural
Products

9

Isotope-Labeled Compounds

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N5021
    Anhydrosafflor yellow B

    AHSYB

    		 Others Neurological Disease
    Anhydrosafflor yellow B (AHSYB) is a quinochalcone C-glycoside isolated from Carthamus tinctorius. Anhydrosafflor yellow B inhibits ADP-induced platelet aggregation, exhibits significant anti-oxidative effects in vitro, and possesses certain activity against H2O2-induced cytotoxicity in cultured PC12 cells and primary neuronal cells .
    Anhydrosafflor yellow B
  • HY-B0228
    Adenosine
    5+ Cited Publications

    Adenine riboside; D-Adenosine

    		 Nucleoside Antimetabolite/Analog Autophagy Apoptosis Endogenous Metabolite Metabolic Disease Cancer
    Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .
    Adenosine
  • HY-N12840
    Logmalicid B

    		Others Metabolic Disease
    Logmalicid B is an iridoid glycoside compound that can be isolated from Cornus officinalis and can be used in diabetes research .
    Logmalicid B
  • HY-144775
    AChE-IN-10

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-10 (Compound 24r) is a potent inhibitor of AChE (IC50 = 2.4 nM). AChE-IN-10 potently inhibits AChE, reduces tau phosphorylation at S396 residue, provides neuroprotection by rescuing neuronal morphology and increasing cell viability. AChE-IN-10 is also found to reduce amyloid aggregation in the presence of AChE .
    AChE-IN-10
  • HY-B0228S13
    Adenosine-13C10

    Adenine riboside-13C10; D-Adenosine-13C10

    		 Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog Endogenous Metabolite Autophagy Apoptosis Metabolic Disease Cancer
    Adenosine- 13C10 (Adenine riboside- 13C10; D-Adenosine- 13C10) is 13C-labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
    Adenosine-13C10
  • HY-B0228S12
    Adenosine-d13

    Adenine riboside-d13; D-Adenosine-d13

    		 Isotope-Labeled Compounds Nucleoside Antimetabolite/Analog Endogenous Metabolite Autophagy Apoptosis Metabolic Disease Cancer
    Adenosine-d13 (Adenine riboside-d13; D-Adenosine-d13) is deuterium labeled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.
    Adenosine-d13
  • HY-B0228S11
    Adenosine-15N5

    Adenine riboside-15N5; D-Adenosine-15N5

    		 Isotope-Labeled Compounds Cancer
    Adenosine- 15N5 (Adenine riboside- 15N5; D-Adenosine- 15N5) is the 15N labled Adenosine (HY-B0228). Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation .
    Adenosine-15N5
  • HY-161448
    Tau-aggregation-IN-3

    		Tau Protein Neurological Disease
    Tau-aggregation-IN-3 (compound 9) a Tau protein aggregation inhibitor (TAI). Tau-aggregation-IN-3 shows activity in cell-based aggregation inhibition experiments (EC50=4.816 μM). Tau-aggregation-IN-3 can be used in Alzheimer's disease research .
    Tau-aggregation-IN-3
  • HY-149763
    Aβ42 agonist-1

    		Amyloid-β Neurological Disease
    Aβ42 agonist-1 (compound 7a) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-1 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-1 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
    Aβ42 agonist-1
  • HY-146005
    Tau-aggregation and neuroinflammation-IN-1

    		Microtubule/Tubulin Neurological Disease Inflammation/Immunology
    Tau-aggregation and neuroinflammation-IN-1 is a potent tau-aggregation and neuroinflammation inhibitor. Tau-aggregation and neuroinflammation-IN-1 exhibits remarkable inhibitory activities against AcPHF6 and full-length tau aggregation. Tau-aggregation and neuroinflammation-IN-1 has a low cytotoxicity and reduced NO release in LPS-stimulated BV2 cells. Tau-aggregation and neuroinflammation-IN-1 can reverse okadaic acid-induced memory impairment in rats .
    Tau-aggregation and neuroinflammation-IN-1
  • HY-149764
    Aβ42 agonist-2

    		Amyloid-β Neurological Disease
    Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .
    Aβ42 agonist-2
  • HY-16662
    Oncrasin-1

    		Ras Apoptosis Cancer
    Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations; also led to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells.
    Oncrasin-1
  • HY-121377
    Epiyangambin

    		Platelet-activating Factor Receptor (PAFR) Inflammation/Immunology Cancer
    Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells) .
    Epiyangambin
  • HY-D1005A18
    Poloxamer 288 (F98)

    PEG-PPG-PEG, 13000 (Averag)

    		 Biochemical Assay Reagents Others
    Poloxamer 288 F98 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 13000. Poloxamer 288 F98 reduces the aggregation of red blood cells .
    Poloxamer 288 (F98)
  • HY-N2081
    Skimmianine
    1 Publications Verification

    		 Others Inflammation/Immunology Cancer
    Skimmianine is a furoquinoline alkaloid present mainly in the Rutaceae family, with antispastic, anti-inflammatory activities and antiplatelet aggregation effect. Skimmianine exhibits cytotoxicity against a variety of cancer cell lines and genotoxicity .
    Skimmianine
  • HY-106745
    Elziverine

    Ro 22-4839

    		 Calmodulin Cardiovascular Disease
    Elziverine (Ro 22-4839) is a brain circulation improvement agent with vasospasm antispasmodic effects. Elziverine is a calmodulin antagonist. Elziverine inhibits erythrocyte cell membrane rupture, platelet aggregation and lipid peroxidation .
    Elziverine
  • HY-146140
    Aβ-IN-4

    		Amyloid-β Neurological Disease
    Aβ-IN-4 (compound 12) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-4 inhibits Aβ42 aggregation. However, Aβ-IN-4 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-4 can not change the aggregation state of Aβ42 into a nontoxic one .
    Aβ-IN-4
  • HY-146139
    Aβ-IN-3

    		Amyloid-β Neurological Disease
    Aβ-IN-3 (compound 1) is a potent amyloid β (Aβ) inhibitor. Aβ-IN-3 inhibits Aβ42 aggregation. However, Aβ-IN-3 can not alleviate the neurotoxicity of Aβ42 in SH-SY5Y cells. Aβ-IN-3 can not change the aggregation state of Aβ42 into a nontoxic one .
    Aβ-IN-3
  • HY-17000
    Tolvaptan
    Maximum Cited Publications
    10 Publications Verification

    OPC-41061

    		 Vasopressin Receptor Autophagy Cardiovascular Disease Endocrinology Cancer
    Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .
    Tolvaptan
  • HY-W127502
    1-Hexadecylglycero-3-phosphate

    1-Hex-GPA

    		 Biochemical Assay Reagents Others
    1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.
    1-Hexadecylglycero-3-phosphate
  • HY-D1005A22
    Poloxamer 338 (F108)

    PEG-PPG-PEG, 14600 (Averag)

    		 Biochemical Assay Reagents Others
    Poloxamer 338 F108 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 14600. Poloxamer 338 F108 reduces the aggregation of red blood cells, inhibits proliferation of human lymphocyte cell IIBR1. Poloxamer 338 F108 exhibits short-term and subchronic toxicity in rats .
    Poloxamer 338 (F108)
  • HY-Y0152
    Cinchonine
    2 Publications Verification

    (8R,9S)-Cinchonine; LA40221

    		 Apoptosis Parasite Autophagy Caspase Calcium Channel Others Inflammation/Immunology Cancer
    Cinchonine is a natural compound present in Cinchona bark with antimalarial, antitumor, anti-inflammatory, anti platelet-aggregation and anti-obesity properties. Cinchonine inhibits cells proliferation and autophagy and induces apoptosis through activation of Caspase-3. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells .
    Cinchonine
  • HY-17406S
    Tolcapone-d7

    Ro 40-7592 d7

    		 Isotope-Labeled Compounds COMT Amyloid-β Neurological Disease
    Tolcapone-d7 is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].
    Tolcapone-d7
  • HY-125197
    BRD5631

    		Autophagy Inflammation/Immunology
    BRD5631 is an autophagy enhancer, enhances autophagy through an mTOR-independent pathway. BRD5631 affects several cellular disease phenotypes previously linked to autophagy, including protein aggregation, cell survival, bacterial replication, and inflammatory cytokine production .
    BRD5631
  • HY-151940
    Mal-Pc

    		Reactive Oxygen Species Cancer
    Mal-Pc is a versatile molecular photosensitizer designed based phthalocyanine and maleimides. Mal-Pc can react with GSH to deplete GSH and reduce aggregation, thereby improving ROS (Reactive Oxygen Species)-mediated effect of photodynamic therapy (PDT) in cancer cells .
    Mal-Pc
  • HY-149375
    Tubulin inhibitor 37

    		Microtubule/Tubulin Cancer
    Tubulin inhibitor 37 (Compound 12) is a Tubulin inhibitor that can effectively inhibit Tubulin aggregation (IC50=1.3 µM). Tubulin inhibitor 37 exhibits antiproliferative activity against human tumor cell lines and has potential for studying cancer .
    Tubulin inhibitor 37
  • HY-15583
    Auristatin F

    		ADC Cytotoxin Microtubule/Tubulin Cancer
    Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F
  • HY-N2892
    Aristolactam A IIIa

    Aristololactam A IIIa; Sch 546909

    		 DYRK Cardiovascular Disease Cancer
    Aristolactam A IIIa (Sch 546909) is an aristolactam-type alkaloid that can be isolated from Glycosmis chlorosperma. Aristolactam A IIIa is a DYRK1A Inhibitor. Aristolactam A IIIa inhibits platelet aggregation induced by arachidonic acid (AA), collagen and platelet-activating factor (PAF). Aristolactam A IIIa has strong cytotoxic effect on HeLa cells .
    Aristolactam A IIIa
  • HY-134556
    2'-Hydroxyflavanone

    		Apoptosis Inflammation/Immunology Cancer
    2'-Hydroxyflavanone is a flavanone that can inhibit cancer cell proliferation, induce apoptosis, and reduce inflammation. 2'-Hydroxyflavanone shows inhibitory effect on platelet aggregation caused by two inducers with IC50s 47.8 μM arachidonic acid (AA) and 147.2 μM aenosine diphosphate (ADP) .
    2'-Hydroxyflavanone
  • HY-107615
    TC LPA5 4

    		LPL Receptor Cancer
    TC LPA5 4 is a LPA5 (GPR92)-specific non-lipid antagonist. TC LPA5 4 inhibits LPA-induced aggregation of isolated human platelet (LPA5-RH7777 cell line) with an IC50 of 800 nM. TC LPA5 4 displays selectivity for LPA5 over 80 other screened agent targets . TC LPA5 4 inhibits cell proliferation and migration of thyroid cancer cells .
    TC LPA5 4
  • HY-D1468
    Phototherapeutic agent-1

    		Reactive Oxygen Species Cancer
    Phototherapeutic agent-1 is a multi-modal light diagnosis agent with aggregation-induced emission properties. have certain Phototherapeutic agent-1 has certain reactive oxygen species (ROS) generation capacity in illumination condition. Phototherapeutic agent-1 can effectively kill cancer cells and tumor tissue .
    Phototherapeutic agent-1
  • HY-D1005A17
    Poloxamer 238 (F88)

    PEG-PPG-PEG, 11400 (Averag)

    		 Biochemical Assay Reagents Others
    Poloxamer 238 F88 is block polymer of polyoxyethylene and polyoxypropylene with average molecular mass of 11400. Poloxamer 238 F88 reduces the aggregation of red blood cells. Poloxamer 238 F88 forms thermoreversible hydrogel, that is utilized in food additives, drug delivery carriers in cosmetics, pharmaceutical ingredients and tissue engineering .
    Poloxamer 238 (F88)
  • HY-W009276
    γ-Linolenic Acid methyl ester

    Methyl GLA

    		 Apoptosis Cancer
    γ-Linolenic Acid methyl ester (Methyl GLA) is an esterified version of γ-Linolenic Acid (GLA), which is an ω-6 fatty acid, serves as melanoma cell proliferation inhibitors. γ-Linolenic Acid methyl ester inhibits ADP-induced blood platelet aggregation and induces apoptosis .
    γ-Linolenic Acid methyl ester
  • HY-18377
    Bioymifi

    DR5 Activator

    		 TNF Receptor Apoptosis Cancer
    Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
    Bioymifi
  • HY-110052
    TBCA

    		Casein Kinase Cancer
    TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .
    TBCA
  • HY-N0373
    Licochalcone B
    4 Publications Verification

    		 Amyloid-β Apoptosis NOD-like Receptor (NLR) Neurological Disease
    Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .
    Licochalcone B
  • HY-145785
    ADH-6

    		MDM-2/p53 Apoptosis Cancer
    ADH-6 is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 has the potential for the research of cancer diseases[1].
    ADH-6
  • HY-N3187
    Nimbin

    		Flavivirus Dengue virus Fungal Bacterial Histamine Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Nimbin is a intermediate limonoid isolated from Azadirachta. Nimbin prevents tau aggregation and increases cell viability. Nimbin is effective inhibits the envelope protein of dengue virus. Nimbin has anti-inflammatory, antipyretic, antifungal, antihistamine, antiseptic, antioxidant, anti-cancer and anti-viral properties. Nimbin can across blood-brain barrier .
    Nimbin
  • HY-157978
    AChE-IN-59

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE-IN-59 (compounds 3b) is an AChE inhibitor, with an IC50 value of 0.05 μM. AChE-IN-59 can inhibit the aggregation of Aβ1-42, protect nerve cells and penetrate the blood-brain barrier well. AChE-IN-59 can be used for the research of Alzheimer's disease (AD) .
    AChE-IN-59
  • HY-145785A
    ADH-6 TFA

    		MDM-2/p53 Apoptosis Cancer
    ADH-6 TFA is a tripyridylamide compound. ADH-6 abrogates self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD. ADH-6 TFA targets and dissociates mutant p53 aggregates in human cancer cells, which restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis. ADH-6 TFA has the potential for the research of cancer diseases .
    ADH-6 TFA
  • HY-Y0152A
    Cinchonine monohydrochloride hydrate

    (8R,9S)-Cinchonine monohydrochloride hydrate; LA40221 monohydrochloride hydrate

    		 Parasite Apoptosis Infection Cardiovascular Disease Metabolic Disease Cancer
    Cinchonine ((8R,9S)-Cinchonine) monohydrochloride hydrate is a natural compound which has been effectively used as antimalarial agent. Cinchonine monohydrochloride hydrate activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells. Cinchonine monohydrochloride hydrate is also an inhibitor of human platelet aggregation. Cinchonine monohydrochloride hydrate possesses a suppressive effect on adipogenesis .
    Cinchonine monohydrochloride hydrate
  • HY-B0523
    Anagrelide

    		Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .
    Anagrelide
  • HY-147938
    AChE-IN-19

    		Cholinesterase (ChE) Amyloid-β Neurological Disease
    AChE-IN-19 (compound A15) is a highly potent AChE inhibitor with an IC50 value of 0.56 μM, also inhibits Aβ aggregation. AChE-IN-19 has potent neuroprotective activities and nearly no toxicity on SH-SY5Y cells. AChE-IN-19 can be used for researching Alzheimer's disease .
    AChE-IN-19
  • HY-B0523B
    Anagrelide hydrochloride monohydrate

    		Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Anagrelide hydrochloride monohydrate is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride monohydrate, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride monohydrate inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride monohydrate decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride monohydrate is a platelet-lowering agent and plays in the antithrombopoietic action .
    Anagrelide hydrochloride monohydrate
  • HY-B0523A
    Anagrelide hydrochloride
    2 Publications Verification

    BL4162A

    		 Phosphodiesterase (PDE) Apoptosis Cardiovascular Disease Cancer
    Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .
    Anagrelide hydrochloride
  • HY-15583S
    Auristatin F-d8

    		Isotope-Labeled Compounds ADC Cytotoxin Microtubule/Tubulin Cancer
    Auristatin F-d8 is deuterium labeled Auristatin F (HY-15583). Auristatin F is a potent cytotoxin in antibo-conjugated agents and an analogue of MMAF. Auristatin F is a potent microtubule inhibitor and vascular damaging agent (VDA). Auristatin F inhibits cell division by preventing tubulin aggregation.Auristatin F can be used in antibody-drug conjugates (ADC) .
    Auristatin F-d8
  • HY-B0228S
    Adenosine-d1

    Adenine riboside-d1; D-Adenosine-d

    		 Nucleoside Antimetabolite/Analog Autophagy Apoptosis Endogenous Metabolite Metabolic Disease Cancer
    Adenosine-d is the deuterium labeled Adenosine. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[1][2].
    Adenosine-d1
  • HY-124582
    NEO214

    		Autophagy mTOR Cancer
    NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .
    NEO214
  • HY-13270
    ABT-751

    E7010

    		 Microtubule/Tubulin Autophagy Apoptosis Cancer
    ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer .
    ABT-751
  • HY-B0228S1
    Adenosine-13C5

    Adenine riboside-13C5; D-Adenosine-13C5

    		 Apoptosis Nucleoside Antimetabolite/Analog Autophagy Endogenous Metabolite
    Adenosine- 13C5 is the 13C labeled Adenosine[1]. Adenosine (Adenine riboside), a ubiquitous endogenous autacoid, acts through the enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Adenosine affects almost all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation[2][3].
    Adenosine-13C5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: